Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Supernus Pharmaceuticals, Inc.
Age
18–45
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Participant either must have ceased lactating at screening; or if still lactating or actively breastfeeding at screening, agreed to temporarily cease giving breastmilk to their infant(s).
Participant had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I).
Participant had a HAM-D total score of ≥20 and ≤25 at screening and Day 1 (prior to dosing).
Participant was ≤ six months postpartum.
Participant was amenable to intravenous therapy.
You may not be if
Active psychosis.
Attempted suicide associated with index case of postpartum depression.
Medical history of bipolar disorder.
Clareo Health | A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
